iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of drugs by first binding to av integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.
| Molecular Weight | 948.04 |
| Formula | C35H57N13O14S2 |
| CAS Number | 1392278-76-0 |
| Solubility (25°C) | Water ≥ 50 mg/mL |
| Storage | -20°C, protect from light, dry, sealed |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[5] Hong Yin, et al. Mol Med Rep. iRGD as a tumor‑penetrating peptide for cancer therapy (Review)
| Related Integrin Products |
|---|
| SGN-B6A
SGN-B6A is an integrin-targeted ADC that selectively targets solid tumors by recognizing ITGB6. |
| Alintegimod
Alintegimod is an orally active variant activator of integrins αLβ2 and α4β1 that enhances T cell activation and adhesion. |
| OS2966
OS2966 is a first-in-class (first-in-class) neutralizing anti-CD29 monoclonal antibody that selectively modulates CD29 (integrin b1 subunit) and can be used in glioblastoma-related studies. |
| JSM-6427
JSM-6427 is an integrin α5β1 antagonist. |
| MORF-057
MORF-057 is an oral small molecule α4β7 integrin (integrin) inhibitor that can be used in studies related to ulcerative colitis (UC). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
